TuHURA Biosciences (NASDAQ:HURA – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.
Several other analysts have also issued reports on HURA. Citizens Jmp reiterated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.
Read Our Latest Report on HURA
TuHURA Biosciences Trading Down 4.3%
Shares of TuHURA Biosciences stock opened at $1.33 on Tuesday. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $3.43. The company has a market capitalization of $84.76 million, a price-to-earnings ratio of -2.66 and a beta of -0.23. The firm’s 50-day moving average price is $1.90 and its two-hundred day moving average price is $2.00.
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. On average, analysts forecast that TuHURA Biosciences will post -0.57 earnings per share for the current fiscal year.
Institutional Trading of TuHURA Biosciences
Several large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $1,615,000. Jefferies Financial Group Inc. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at approximately $98,000. Invst LLC bought a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at approximately $99,000. Hsbc Holdings PLC acquired a new position in TuHURA Biosciences during the 2nd quarter worth approximately $69,000. Finally, Sanctuary Advisors LLC acquired a new position in TuHURA Biosciences during the 2nd quarter worth approximately $49,000. 0.62% of the stock is owned by institutional investors and hedge funds.
About TuHURA Biosciences
TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.
Featured Articles
- Five stocks we like better than TuHURA Biosciences
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
